These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 30656853)
21. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials. Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515 [TBL] [Abstract][Full Text] [Related]
22. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis. Chan TLH; Cowan RP; Woldeamanuel YW Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018 [TBL] [Abstract][Full Text] [Related]
23. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis. Ha DK; Kim MJ; Han N; Kwak JH; Baek IH Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614 [TBL] [Abstract][Full Text] [Related]
24. Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison. Lu J; Zhang Q; Guo X; Liu W; Xu C; Hu X; Ni J; Lu H; Zhao H Front Pharmacol; 2021; 12():631204. PubMed ID: 34012392 [No Abstract] [Full Text] [Related]
25. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292 [TBL] [Abstract][Full Text] [Related]
26. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine. Maasumi K; Michael RL; Rapoport AM Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205 [TBL] [Abstract][Full Text] [Related]
27. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. Israel H; Neeb L; Reuter U Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520 [TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. Alasad YW; Asha MZ Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review. Jiang Y; Huang ZL Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta-analysis. Siahaan YMT; Hartoyo V; Hariyanto TI Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1156-1168. PubMed ID: 35781694 [TBL] [Abstract][Full Text] [Related]
31. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class. Arca K; Reynolds J; Sands KA; Shiue HJ Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317 [No Abstract] [Full Text] [Related]
32. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine. Cohen F; Yuan H; DePoy EMG; Silberstein SD Neurotherapeutics; 2022 Apr; 19(3):922-930. PubMed ID: 35426060 [TBL] [Abstract][Full Text] [Related]
33. Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention. Regnier SA; Lee XY J Med Econ; 2023; 26(1):1072-1080. PubMed ID: 37594778 [No Abstract] [Full Text] [Related]
34. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. Wang X; Wen D; He Q; You C; Ma L J Headache Pain; 2022 Sep; 23(1):105. PubMed ID: 36071388 [TBL] [Abstract][Full Text] [Related]
35. Medications Approved for Preventing Migraine Headaches. Spindler BL; Ryan M Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209 [TBL] [Abstract][Full Text] [Related]
36. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405 [TBL] [Abstract][Full Text] [Related]
37. CGRP inhibitors for migraine prophylaxis: a safety review. Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190 [TBL] [Abstract][Full Text] [Related]
38. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Foster SA; Hoyt M; Ye W; Mason O; Ford JH Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723 [TBL] [Abstract][Full Text] [Related]
39. "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Asawavichienjinda T; Sathitratanacheewin S; Chokesuwattanaskul R Cephalalgia; 2023 Apr; 43(4):3331024231161261. PubMed ID: 36924253 [TBL] [Abstract][Full Text] [Related]
40. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. Siersbæk N; Kilsdal L; Jervelund C; Antic S; Bendtsen L BMC Neurol; 2023 Jul; 23(1):254. PubMed ID: 37400756 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]